Peer-reviewed veterinary case report
Live vaccine with Leishmania major p27 gene knockout protects dogs
By Elikaee, S et al.·Published in Acta tropica·2022·Department of Medical Parasitology and Mycology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Live attenuated Leishmania major p27 gene knockout as a novel vaccine candidate: A study on safety, protective immunity and efficacy against canine leishmaniasis caused by Leishmania infantum.
- Species:
- dog
Plain-English summary
A study tested a new vaccine for dogs against leishmaniasis, a serious disease caused by the Leishmania infantum parasite, which is spread by sand flies. The vaccine, called Lmp27, was given to dogs and showed no harmful effects over a year. The vaccinated dogs had stronger immune responses and lower levels of the parasite when later exposed to it. This suggests that the Lmp27 vaccine could be a safe and effective way to protect dogs from leishmaniasis.
People also search for: dog leishmaniasis vaccine · canine leishmaniasis symptoms · how to prevent leishmaniasis in dogs
Abstract
Canine leishmaniasis (CanL) is an important parasitic e disease caused by Leishmania infantum and is transmitted by female phlebotomine sand flies primarily between canines and secondarily to humans. Recently, we showed that immunization with Leishmania major p27 gene knockout (Lmp27) as a live attenuated vaccine was safe, induced immunogenicity, and protected against the development cutaneous and visceral leishmaniasis in mice. The p27 protein is a component of the COX protein complex which is responsible for ATP production. In this study, we analyzed the Lmp27candidate vaccine potential with this regard to the safety and induction of immunogenicity and protection against CanL. Variables such a clinical manifestation, anti-Leishmania antibodies using direct agglutination test (DAT), lymphocyte proliferation, delayed-type hypersensitivity (DTH), bone marrow aspiration (BMA) and parasite burden using parasitological and molecular examinations were measured. The results demonstrated that the Lmp27vaccinated group showed no clinical signs after inoculation with Lmp27mutant during a 12-month follow-up, and had significantly higher T-cell responses (Lymphocyte proliferation and DTH), lower seroconversion and parasite burdens following a challenge inoculation with L. infantum after 6-mounth. In conclusion, vaccination with Lmp27parasites would be safe and provide significant immunoprotectivity and efficacy against infection with wild type (WT) L. infantum.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34634264/